GH Research PLC (GHRS): רווח נקי למניה ב-12 החודשים האחרונים
GH Research PLC (GHRS) is at the beginning of a global scientific and technological cycle where asset value is tied to clinical success. The change in the rolling annual EPS demonstrates this trend, and the value of -0.99 corresponds to the current metric. Growth is driven by the automation of substance synthesis, although physicians maintain patient control. However, threats from DEA regulators and the lack of patent protection for methods remain.
%20%D7%A8%D7%95%D7%95%D7%97%20%D7%A0%D7%A7%D7%99%20%D7%9C%D7%9E%D7%A0%D7%99%D7%94%20%D7%90%D7%97%D7%AA%20%D7%91%D7%A9%D7%A0%D7%99%D7%9D%20%D7%A2%D7%A9%D7%A8%20%D7%94%D7%97%D7%95%D7%93%D7%A9%D7%99%D7%9D%20%D7%94%D7%90%D7%97%D7%A8%D7%95%D7%A0%D7%99%D7%9D&width=1200&height=400&colorIndex=0&v=mwhdatcg.m7-7dqbc3k&start=20220704&end=20261115&filename=GURU_Markets_-_GHRS_-_GH-Research-PLC_-_Net-earnings-per-one-share-for-the-last-twelve-months "רווח נקי למניה (EPS TTM) GH Research PLC (GHRS): לתקופה 04.07.2022 - 15.11.2026 | 👁️GURU.Markets👁️")
פילוחים אנליטיים ודוחות נתונים של חברת GH Research Corp (GHRS)
This indicator reflects the portion of net income attributable to a single ordinary share over the last twelve months, allowing for an assessment of real capital generation efficiency. By analyzing the fundamental TTM earnings per share, an investor can see the impact of high R&D expenses at GH Research PLC (GHRS), which temporarily reduce current yields pending the publication of Phase 2 clinical trial results.
